Back to Resource Library
Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study
The Ring Study, a phase 3 trial, showed a favourable safety profile and a 31% HIV infection risk reduction for a vaginal ring containing 25 mg of dapivirine, compared with a placebo ring. This article outlines the DREAM study, which aimed to evaluate safety, adherence, and HIV incidence in those using the dapivirine vaginal ring (DVR) in open-label use.